Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees

The adaptive immune response to vaccination or infection can lead to the production of specific antibodies to neutralize the pathogen or recruit innate immune effector cells for help. The non-neutralizing role of antibodies in stimulating effector cell responses may have been a key mechanism of the protection observed in the RV144 HIV vaccine trial. In an extensive investigation of a rich set of data collected from RV144 vaccine recipients, we here employ machine learning methods to identify and model associations between antibody features (IgG subclass and antigen specificity) and effector function activities (antibody dependent cellular phagocytosis, cellular cytotoxicity, and cytokine release). We demonstrate via cross-validation that classification and regression approaches can effectively use the antibody features to robustly predict qualitative and quantitative functional outcomes. This integration of antibody feature and function data within a machine learning framework provides a new, objective approach to discovering and assessing multivariate immune correlates.

[1]  J. Mascola,et al.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.

[2]  J. Margolick,et al.  HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. , 1996, Journal of immunology.

[3]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[4]  Saravudh Suvannadabba,et al.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial , 2012, The Lancet.

[5]  G. Carrasquilla,et al.  Efficacy of a tetravalent dengue vaccine in children in Latin America. , 2015, The New England journal of medicine.

[6]  Carl E. Rasmussen,et al.  In Advances in Neural Information Processing Systems , 2011 .

[7]  C. Bailey-Kellogg,et al.  High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. , 2012, Journal of immunological methods.

[8]  Corinna Cortes,et al.  Support-Vector Networks , 1995, Machine Learning.

[9]  S. Plotkin Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.

[10]  Chaim A. Schramm,et al.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.

[11]  R. Tibshirani Regression Shrinkage and Selection via the Lasso , 1996 .

[12]  Tomer Hertz,et al.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2 , 2012, Nature.

[13]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[14]  R. Haubrich,et al.  Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. , 1999, The Journal of infectious diseases.

[15]  D. Venzon,et al.  A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. , 2006, Journal of immunological methods.

[16]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[17]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[19]  Malika Charrad,et al.  NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set , 2014 .

[20]  Robin A. Weiss,et al.  Neutralizing antibodies to HIV-1 induced by immunization , 2013, The Journal of experimental medicine.

[21]  R. Tibshirani,et al.  Least angle regression , 2004, math/0406456.

[22]  S. Kent,et al.  Activation of NK Cells by ADCC Antibodies and HIV Disease Progression , 2011, Journal of acquired immune deficiency syndromes.

[23]  D. Irvine,et al.  A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.

[24]  J. H. Ward Hierarchical Grouping to Optimize an Objective Function , 1963 .

[25]  Gary J. Nabel,et al.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.

[26]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[27]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[28]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[29]  Jerome H. Kim,et al.  Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines , 2014, Science Translational Medicine.

[30]  J. Goeman L1 Penalized Estimation in the Cox Proportional Hazards Model , 2009, Biometrical journal. Biometrische Zeitschrift.

[31]  Bernhard Schölkopf,et al.  New Support Vector Algorithms , 2000, Neural Computation.

[32]  Jerome H. Kim,et al.  Machine Learning Methods Enable Predictive Modeling of Antibody Feature : Function Relationships in RV 144 Vaccinees , 2015 .

[33]  G. Alter,et al.  Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. , 2012, Annual review of medicine.

[34]  Alexander J. Smola,et al.  Support Vector Regression Machines , 1996, NIPS.

[35]  Chih-Jen Lin,et al.  LIBSVM: A library for support vector machines , 2011, TIST.

[36]  M. Altfeld,et al.  Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.

[37]  C. Bailey-Kellogg,et al.  Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. , 2013, The Journal of clinical investigation.

[38]  George C. Runger,et al.  Feature selection via regularized trees , 2012, The 2012 International Joint Conference on Neural Networks (IJCNN).

[39]  P. Bruhns Properties of mouse and human IgG receptors and their contribution to disease models. , 2012, Blood.